Tag: HD-MAP
Vaxxas hits enrollment target in trial of HD-MAP technology for pandemic response
Australian biotechnology company Vaxxas has completed enrollment for its largest clinical trial to date, testing the safety and immune response of its high-density microarray patch (HD-MAP) for vaccine delivery.
Vaxxas unveils positive clinical trial results for needle-free COVID-19 vaccine
Australia biotechnology company Vaxxas said it achieved positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate.
Vaxxas kickstarts needle-free COVID-19 vaccine clinical trial
Australian biotechnology company Vaxxas has begun the Phase I clinical trial of the first needle-free COVID-19 vaccine candidate.
Vaxxas receives $8.2 million Commonwealth Government grant to support manufacturing scale-up in its Australian...
Media Release by Vaxxas
Vaxxas will receive an AU$8.2 million second-round grant as part of the Commonwealth Government’s Modern Manufacturing Initiative (MMI) to support the...
Construction commences of Australia’s first needle-free vaccine manufacturing facility
Vaxxas, a Queensland biotechnology business, has begun construction on a new facility in Northshore Hamilton, Brisbane to develop and manufacture its needle-free vaccination technology.
The...
Featured Article
Driving the future of smart energy: GridBeyond and ABB unveil new white paper on battery storage innovation
As industries adopt cleaner, more intelligent energy solutions, the ability to manage, store, and trade energy efficiently is increasingly vital to sustaining a competitive edge.
